ArticleCancers2024

Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial Cancer.

Hitomi Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.